Patents by Inventor Rosemary Lynch

Rosemary Lynch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Curing compositions
    Patent number: 9926404
    Abstract: Epoxy compositions include a cucurbituril in complex with a curative, and methods for curing the epoxy composition. The curative is reactive with an epoxy compound, and the curative may be a cure accelerator or a cure hardener. Cured resins are obtained or obtainable from the epoxy compositions. Complexes of a cucurbituril have a curative.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 27, 2018
    Assignee: AQDOT LIMITED
    Inventors: Ben Cheesman, Roger Coulston, Rosemary Lynch, Matthew Rowland, David Diec
  • Heterocyclyl pyrimidine analogues as TYK2 inhibitors
    Patent number: 9655897
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 23, 2017
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • CURING COMPOSITIONS
    Publication number: 20160340467
    Abstract: Epoxy compositions include a cucurbituril in complex with a curative, and methods for curing the epoxy composition. The curative is reactive with an epoxy compound, and the curative may be a cure accelerator or a cure hardener. Cured resins are obtained or obtainable from the epoxy compositions. Complexes of a cucurbituril have a curative.
    Type: Application
    Filed: May 18, 2016
    Publication date: November 24, 2016
    Applicant: AQDOT LIMITED
    Inventors: Ben CHEESMAN, Roger COULSTON, Rosemary LYNCH, Matthew ROWLAND, David DIEC
  • Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
    Publication number: 20160184307
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: March 3, 2016
    Publication date: June 30, 2016
    Inventors: Richard John HARRISON, Nigel RAMSDEN, Jeremy MAJOR, Adeline MOREL, Laura CONVERY, Mihiro SUNOSE, Rosemary LYNCH, Rita ADREGO, Alison JONES
  • Heterocyclyl pyrimidine analogues as TYK2 inhibitors
    Patent number: 9296725
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: March 29, 2016
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Morpholino substituted urea derivatives as mTOR inhibitors
    Patent number: 9249129
    Abstract: The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, and n have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: February 2, 2016
    Assignee: CELLZOME LIMITED
    Inventors: Jessica Taylor, Daniel Paul Hardy, Rosemary Lynch, Helen Sarah Niblock, Andrew David Cansfield
  • Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
    Patent number: 9242993
    Abstract: The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 26, 2016
    Assignee: CELLZOME LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, John Thomas Feutrill, Rita Adrego, Katie Ellard, Tammy Ladduwahetty
  • Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
    Patent number: 9175011
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 3, 2015
    Assignee: CELLZONE LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
    Publication number: 20150166513
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 18, 2015
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140378438
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Application
    Filed: September 21, 2012
    Publication date: December 25, 2014
    Applicant: CELLZOME LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140296234
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Rosemary LYNCH, Andrew David CANSFIELD, Helen Sarah NIBLOCK, Daniel HARDY, Jane Elizabeth SCANLON, Rita ADREGO, Nigel RAMSDEN
  • MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140288066
    Abstract: The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, John Thomas Feutrill, Rita Adrego, Katie Ellard, Tammy Ladduwahetty
  • Pyrimidine derivatives as mTOR inhibitors
    Patent number: 8785457
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. The compounds of formula (I) are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Cellzome Limited
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden
  • DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140163023
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T0, o have the meaning as cited in the description and the claims. The compounds of formula I are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds of formula I, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: April 2, 2012
    Publication date: June 12, 2014
    Applicant: Cellzome Limited
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Jane Elizabeth Scanlon, Rita Joana Rodrigues Adrego
  • MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20130196982
    Abstract: The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, n have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: March 4, 2011
    Publication date: August 1, 2013
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Paul Hardy, Jessica Taylor
  • Arginine Derivatives with NP-I Antagonistic Activity
    Publication number: 20120269864
    Abstract: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 25, 2012
    Inventors: Haiyan Jia, Ian ZACHARY, Michelle TICKNER, Lili CHENG, Chris CHAPMAN, Katie ELLARD, Basil HARTZOULAKIS, Ashley JARVIS, Rosemary LYNCH, Jamie NALLY, David SELWOOD, Mark STEWART
  • Arginine derivatives with NP-1 antagonistic activity
    Patent number: 8227606
    Abstract: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: July 24, 2012
    Assignee: Ark Therapeutics, Ltd.
    Inventors: Haiyan Jia, Ian Zachary, Michelle Tickner, Lili Cheng, Chris Chapman, Katie Ellard, Basil Hartzoulakis, Ashley Jarvis, Rosemary Lynch, Jamie Nally, David Selwood, Mark Stewart
  • ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY
    Publication number: 20120122862
    Abstract: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 17, 2012
    Inventors: Haiyan Jia, Ian Zachary, Michelle Tickner, Lili Cheng, Chris Chapman, Katie Ellard, Basil Hartzoulakis, Ashley Jarvis, Rosemary Lynch, Jamie Nally, David Selwood, Mark Stewart
  • Arginine derivatives with NP-I antagonistic activity
    Patent number: 8158789
    Abstract: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: April 17, 2012
    Assignee: Ark Therapeutics Group Ltd.
    Inventors: Haiyan Jia, Ian Zachary, Michelle Tickner, Lili Cheng, Chris Chapman, Katie Ellard, Basil Hartzoulakis, Ashley Jarvis, Rosemary Lynch, Jamie Nally, David Selwood, Mark Stewart
  • PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
    Publication number: 20120065202
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 15, 2012
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden